Prime Medicine (PRME) Cash from Financing Activities (2021 - 2026)
Prime Medicine's (PRME) quarterly Cash from Financing Activities came in at $393000.0 in Q1 2026, down 93.45% YoY from $6.0 million in Q1 2025, and down 30.07% on a QoQ basis from $562000.0 in Q4 2025.
Prime Medicine (PRME) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Cash from Financing Activities data on file, last reported at $393000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 93.45% year-over-year to $393000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.9 million (up 227.52% YoY) and the FY2025 annual result came in at $151.5 million, down 22.65% from the prior year.
- Cash from Financing Activities eased to $393000.0 in Q1 2026, from $562000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $184.1 million in Q4 2022 to a low of -$1.3 million in Q1 2022.
- A 5-year average of $31.2 million and a median of $197000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 99.89% — and 2024, when it soared 231263.24%.
- Tracing PRME's Cash from Financing Activities over 5 years: stood at $184.1 million in 2022, then slumped by 99.89% to $194000.0 in 2023, then plunged by 99.48% to $1000.0 in 2024, then soared by 56100.0% to $562000.0 in 2025, then plunged by 30.07% to $393000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $393000.0 (Q1 2026), $562000.0 (Q4 2025), and $144.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 361,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 361,000.00 |
| Jun 30, 2026 | 361,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Dec 31, 2025 | 562,000.00 |
| Sep 30, 2025 | 144.75 Mn |
| Sep 30, 2025 | 144.75 Mn |
| Jun 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 6.00 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 38.51 Mn |
| Sep 30, 2024 | 38.51 Mn |
| Jun 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 157.33 Mn |
| Mar 31, 2024 | 157.33 Mn |